Cypre

Executive Summary

Cypre is a Cambridge-based biotechnology company pioneering advanced 3D tumor organoid models to accelerate oncology drug development. Its proprietary platform integrates human tumor, stromal, and immune cells within a tunable hydrogel matrix, generating high-resolution, predictive data on drug mechanism of action. By providing translational insights from target validation through IND-enabling studies, Cypre partners with pharmaceutical and biotech firms to de-risk drug candidates and improve preclinical-to-clinical success rates. Founded in 2020, the company operates at the intersection of AI, machine learning, and drug delivery, offering a powerful tool for personalized medicine and therapeutic optimization. As a private, pre-clinical stage entity, Cypre is well-positioned to address the critical need for more physiologically relevant tumor models in oncology R&D.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement70% success
• Q4 2026First Major Pharmaceutical Partnership60% success
• Q2 2026Publication of Platform Validation Data in Peer-Reviewed Journal80% success